Evolus Inc., a performance beauty company, has announced the publication of a U.S. pivotal study in the Aesthetic Surgery Journal, detailing the results for its injectable hyaluronic acid gels, Evolysse™ Form and Evolysse™ Smooth. The study demonstrated that both products met the primary endpoint of non-inferiority and showed statistical superiority over the control product, Restylane®-L. The research supports the long-term safety and effectiveness of these gels for correcting dynamic facial wrinkles and folds. Evolysse™ Form achieved more correction with the same amount of product as the control, while Evolysse™ Smooth reached statistical significance at 6 and 9 months despite using 20% less product. The safety profile of both Evolysse™ products was comparable to the control, with no treatment-related serious adverse events reported. Evolus has also received EU Medical Device Regulation approval for its Estyme® brand of HA gels, with plans for a broader European launch in the second half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.